Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.147
Neutral
RSI(14)
51.109
Neutral
STOCH(KDJ)(9,3,3)
28.069
Sell
ATR(14)
1.307
High Vlolatility
CCI(14)
-78.795
Neutral
Williams %R
53.994
Neutral
TRIX(12,20)
0.489
Sell
StochRSI(14)
33.511
Buy
Sarepta Therapeutics Inc
SRPT21.220USD
+0.180+0.86%
Market hours （ET）Quotes delayed by 15 min
2.22BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Sarepta Therapeutics Inc
Currency: USD Updated: 2025-12-19Key Insights
Sarepta Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 90/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 29.46.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sarepta Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
28
analysts
Hold
Current Rating
29.457
Target Price
+34.75%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sarepta Therapeutics Inc Highlights
StrengthsRisks
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 103.85% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -7.79, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 84.30M shares, decreasing 20.58% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 11.84K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 2.36.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Sarepta Therapeutics Inc is 7.28, ranking 121/158 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 399.36M, representing a year-over-year decrease of 14.52%, while its net profit experienced a year-over-year decrease of 635.38%.
Score
Financials
5.81
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.69
Operational Efficiency
10.00
Growth Potential
6.73
Shareholder Returns
7.19
Sarepta Therapeutics Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Sarepta Therapeutics Inc is 7.20, ranking 91/158 in the Pharmaceuticals industry. Its current P/E ratio is -7.79, which is -4841.97% below the recent high of 369.56 and -477.99% above the recent low of -45.04.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 90/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of Sarepta Therapeutics Inc is 6.50, ranking 123/158 in the Pharmaceuticals industry. The average price target for Sarepta Therapeutics Inc is 17.50, with a high of 185.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
28
analysts
Hold
Current Rating
29.457
Target Price
+34.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Sarepta Therapeutics Inc
SRPT
28
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Sarepta Therapeutics Inc is 6.97, ranking 97/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 23.92 and the support level at 17.25, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
21.276
Sell
MA10
21.589
Sell
MA20
21.062
Buy
MA50
20.782
Buy
MA100
19.868
Buy
MA200
32.062
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Sarepta Therapeutics Inc is 7.00, ranking 44/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 80.53%, representing a quarter-over-quarter decrease of 17.95%. The largest institutional shareholder is The Vanguard, holding a total of 10.79M shares, representing 10.30% of shares outstanding, with 12.33% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Two Sigma Investments, LP
Barry (Richard J)
Erste Asset Management GmbH
D. E. Shaw & Co., L.P.
abrdn Inc.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Sarepta Therapeutics Inc is 3.40, ranking 101/158 in the Pharmaceuticals industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.48
VaR
+4.78%
240-Day Maximum Drawdown
+90.67%
240-Day Volatility
+122.65%
Return
Best Daily Return
60 days
+15.68%
120 days
+19.53%
5 years
+30.77%
Worst Daily Return
60 days
-33.74%
120 days
-35.94%
5 years
-42.12%
Sharpe Ratio
60 days
+1.14
120 days
+1.00
5 years
-0.06
Risk Assessment
Maximum Drawdown
240 days
+90.67%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.92
3 years
-0.28
5 years
-0.15
Skewness
240 days
-2.32
3 years
-1.85
5 years
-1.78
Volatility
Realised Volatility
240 days
+122.65%
5 years
--
Standardised True Range
240 days
+13.07%
5 years
+19.40%
Downside Risk-Adjusted Return
120 days
+108.28%
240 days
+108.28%
Maximum Daily Upside Volatility
60 days
+91.94%
Maximum Daily Downside Volatility
60 days
+82.85%
Liquidity
Average Turnover Rate
60 days
+13.38%
120 days
+8.65%
5 years
--
Turnover Deviation
20 days
+236.28%
60 days
+323.40%
120 days
+173.90%
Peer Comparison
Pharmaceuticals
Sarepta Therapeutics Inc
SRPT
6.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Sarepta Therapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Sarepta Therapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Sarepta Therapeutics Inc’s performance and outlook.
How do we generate the financial health score of Sarepta Therapeutics Inc?
To generate the financial health score of Sarepta Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Sarepta Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Sarepta Therapeutics Inc.
How do we generate the company valuation score of Sarepta Therapeutics Inc?
To generate the company valuation score of Sarepta Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Sarepta Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Sarepta Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Sarepta Therapeutics Inc.
How do we generate the earnings forecast score of Sarepta Therapeutics Inc?
To calculate the earnings forecast score of Sarepta Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Sarepta Therapeutics Inc’s future.
How do we generate the price momentum score of Sarepta Therapeutics Inc?
When generating the price momentum score for Sarepta Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Sarepta Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Sarepta Therapeutics Inc.
How do we generate the institutional confidence score of Sarepta Therapeutics Inc?
To generate the institutional confidence score of Sarepta Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Sarepta Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Sarepta Therapeutics Inc.
How do we generate the risk management score of Sarepta Therapeutics Inc?
To assess the risk management score of Sarepta Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Sarepta Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Sarepta Therapeutics Inc.
